8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione 2-amino-2-(hydroxymethyl)-1,3-propanediol anhydrate for the treatment of diseases
申请人:GlaxoSmithKline LLC
公开号:EP2370440B1
公开(公告)日:2014-11-12
Novel Compounds
申请人:GlaxoSmithKline LLC
公开号:US20170027945A1
公开(公告)日:2017-02-02
The present invention relates to a tris salt of 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione of Formula (A):
corresponding manufacture processes, pharmaceutical formulations containing and uses of the aforementioned compound in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
US9163024B2
申请人:——
公开号:US9163024B2
公开(公告)日:2015-10-20
[EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
申请人:GLAXOSMITHKLINE LLC
公开号:WO2010068581A1
公开(公告)日:2010-06-17
The present invention relates to a tris salt of 8-chloro-3-pentyl-3,7-dihydro-1 H-purine- 2,6-dione of Formula (A): corresponding manufacture processes, pharmaceutical formulations containing and uses of the aforementioned compound in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.